SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial

BACKGROUND: The antiviral effects of Novaferon, a potent antiviral protein drug, on COVID-19 was evaluated in the laboratory, and in a randomized, open-label, parallel-group trial. METHODS: In the laboratory, Novaferon's inhibition of viral replication in cells infected with SARS-CoV-2, and pre...

全面介紹

Na minha lista:
書目詳細資料
發表在:Int J Infect Dis
Main Authors: Zheng, Fang, Zhou, Yanwen, Zhou, Zhiguo, Ye, Fei, Huang, Baoying, Huang, Yaxiong, Ma, Jing, Zuo, Qi, Tan, Xin, Xie, Jun, Niu, Peihua, Wang, Wenlong, Xu, Yun, Peng, Feng, Zhou, Ning, Cai, Chunlin, Tang, Wei, Xiao, Xinqiang, Li, Yi, Zhou, Zhiguang, Jiang, Yongfang, Xie, Yuanlin, Tan, Wenjie, Gong, Guozhong
格式: Artigo
語言:Inglês
出版: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7397938/
https://ncbi.nlm.nih.gov/pubmed/32758689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijid.2020.07.053
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍